Enterome to present the significant potential of its Mimicry concept, platform and pipeline at BMO’s Biopharma Spotlight Series conference – Immunology and Inflammation
Paris, France – April 5, 2022
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial effector-based drug discovery platform, announces that its CEO, Pierre Belichard, will present at the BMO Biopharma Spotlight Series conference on Immunology and Inflammation, which will take place virtually April 6, 2022.
Presentation details
Enterome Presentation – Wednesday April 6, 2022 at 1:30 pm EST
Attendee wanting to listen to Enterome (Private) session or other sessions, please access using below.
- Link: https://bmoapps.com
- Event Code: 2022BSS2 (if prompted)
During the presentation, Dr Belichard will provide an overview of the Company’s Molecular Mimicry concept and rationale that underpins its powerful discovery platform as well as the progress it has made with its advanced OncoMimics™ and EndoMimics™ pipelines.
